Equities
Health CareMedical Equipment and Services
  • Price (USD)308.49
  • Today's Change-23.67 / -7.13%
  • Shares traded1.03m
  • 1 Year change-6.55%
  • Beta1.0979
Data delayed at least 15 minutes, as of May 18 2022 21:00 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

DexCom, Inc. is a medical device company. The Company is primarily focused on the design, development, and commercialization of continuous glucose monitoring (CGM), systems for use by people with diabetes and by healthcare providers. Its Dexcom G6 is a CGM system that can be used as part of an integrated system with other compatible medical devices and electronic interfaces, which may include automated insulin dosing systems, insulin pumps, blood glucose meters or other electronic devices used for diabetes management. Its Dexcom Share remote monitoring system, offered for use with its Dexcom system, uses an application on the patient's mobile device to wirelessly transmit glucose information to the cloud and then to applications on the mobile devices of up to five designated recipients. Its Dexcom Real-Time API enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices. Its other products include Dexcom ONE and Dexcom G7.

  • Revenue in USD (TTM)2.57bn
  • Net income in USD211.70m
  • Incorporated1999
  • Employees6.30k
  • Location
    Dexcom Inc6340 Sequence DrSAN DIEGO 92121-4356United StatesUSA
  • Phone+1 (858) 200-0200
  • Fax+1 (302) 636-5454
  • Websitehttps://www.dexcom.com/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
DXCM:NSQ since
announced
Transaction
value
Australasian Medical & Scientific LtdDeal completed01 Aug 202101 Aug 2021Deal completed-40.16%--
Data delayed at least 15 minutes, as of May 18 2022 21:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Cooper Companies Inc3.03bn938.90m16.17bn12.00k17.402.3312.885.3418.8418.8460.74140.770.29431.746.14252,433.309.1214.0910.4615.9966.8065.0330.9934.480.666916.080.31990.338620.228.241,135.1960.807.030.00
Hologic, Inc.5.39bn1.55bn19.26bn6.71k12.714.029.703.576.076.0721.0819.220.61413.935.32804,131.3017.688.3320.4010.1764.2258.3528.7816.162.5722.680.39220.0049.1414.7467.8241.4210.56--
Align Technology, Inc.4.03bn705.94m21.61bn22.54k30.895.8926.395.368.888.8850.7146.530.7324.994.83178,839.0012.8225.1218.2036.5073.6273.4017.5130.361.18--0.000.0059.9029.63-56.5332.4141.55--
Steris PLC4.59bn243.89m21.82bn13.00k91.023.3342.784.762.392.3946.7365.360.50875.776.51--2.695.332.945.8443.9843.085.3010.081.4111.560.310439.4747.5511.90-38.6317.2710.719.17
West Pharmaceutical Services Inc.2.88bn683.00m22.47bn10.07k33.899.6628.687.808.958.9737.7231.390.95484.655.97286,229.5021.9014.1126.6016.7841.3235.6122.9316.012.18150.750.097913.6131.8913.4190.7635.688.297.09
Zimmer Biomet Holdings Inc7.65bn303.20m24.13bn19.50k80.112.0118.053.151.441.0336.4357.330.33531.005.81392,410.301.331.031.491.1669.6271.163.983.310.89186.260.343977.3511.560.4339400.007.13-1.880.00
ResMed Inc.3.54bn779.48m28.80bn7.97k37.108.7830.598.145.315.3124.1022.420.74592.696.60444,101.9016.4311.9819.6214.0356.2957.6622.0217.491.5633.080.171945.578.1111.70-23.676.1311.495.39
DexCom, Inc.2.57bn211.70m31.85bn6.30k158.7614.5496.6412.382.042.0425.4522.320.54462.565.21408,301.604.485.565.216.5068.5367.298.238.914.794.080.48080.0027.0833.69-68.66--47.52--
Baxter International Inc13.55bn1.06bn37.11bn60.00k35.334.0917.492.742.092.0926.7018.030.51913.596.18225,750.004.096.034.747.2239.4541.587.8810.021.459.630.653238.319.524.7016.52-23.700.658916.53
Data as of May 18 2022. Currency figures normalised to Dexcom Inc's reporting currency: US Dollar USD

Institutional shareholders

41.74%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202210.16m10.35%
BlackRock Fund Advisorsas of 31 Mar 20225.59m5.70%
Baillie Gifford & Co.as of 31 Mar 20224.55m4.64%
Sands Capital Management LLCas of 31 Mar 20224.19m4.27%
SSgA Funds Management, Inc.as of 31 Dec 20214.05m4.12%
Fidelity Management & Research Co. LLCas of 31 Mar 20223.49m3.56%
Jennison Associates LLCas of 31 Mar 20222.60m2.65%
Capital Research & Management Co. (Global Investors)as of 31 Dec 20212.37m2.42%
JPMorgan Investment Management, Inc.as of 31 Mar 20222.04m2.08%
Geode Capital Management LLCas of 31 Mar 20221.91m1.95%
More ▼
Data from 31 Dec 2021 - 31 Mar 2022Source: FactSet Research Systems Inc.
An LSEG Business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.